Bloomberg Businessweek

An Alzheimer’s Vaccine Hints of Promise

United Neuroscience’s small Phase II trial appears to have cleared a decades-old hurdle

For two decades, biotech companies trying to tackle Alzheimer’s disease have had little success. While vaccines have often shown promise for certain patients, they’ve come with devastating side effects for others—brain swelling, for example—because researchers haven’t been able to reliably keep patients’ immune systems from kicking into overdrive when exposed to the vaccines. Now, a four-year-old Dublin startup believes it may be on to something.

To be clear, United Neuroscience Inc. hasn’t solved Alzheimer’s yet, nor has it claimed to. But previously unreported results from a small, recent United clinical

You're reading a preview, sign up to read more.

More from Bloomberg Businessweek

Bloomberg Businessweek4 min read
CAN YOU TRUST A Libra?
When Facebook Inc. recently unveiled Libra, its long-awaited cryptocurrency, the company used the announcement as a chance to convey just how much care has gone into the digital asset. David Marcus, the former PayPal Holdings Inc. president who’s the
Bloomberg Businessweek7 min read
Why Walmart Loves Ellen
Ellen DeGeneres is on television every weekday. Sometimes she’s on twice. Her daytime talk show, The Ellen DeGeneres Show, brings in more advertising revenue than Dr. Phil’s and Kelly Ripa’s combined, and her prime-time special, Ellen’s Game of Games
Bloomberg Businessweek2 min read
Dangerous Beauty
The beauty industry has come a long way since the days of arsenic scrubs and lead-based face creams. But maybe it hasn’t come far enough. Earlier this year the U.S. Food and Drug Administration confirmed that asbestos—a known carcinogen that’s unsafe